$ARVN

Arvinas (ARVN) reported Q2 2026 revenue of $249.7 million, including $62.5 million from a Rigel license and a $50 million Pfizer (PFE) milestone tied to FDA approval of VEPPANU. Net income was $169.4 million and diluted EPS $2.58. Cash and marketable securities were $567.9 million, funding into 2H 2028. The call also discussed clinical timing updates and an FDA-requested delay for ARV-102.

Morgan Stanley lowered its price target on Arvinas, Inc. to $10 from $11 and kept an Equalweight rating, according to the note cited in the article. The stock was shown at about $8.75 at the time of publication.

Arvinas shares rose 13.2% after the company reported Q2 2026 results before the open. EPS was $2.58 versus a forecast loss of $0.38, and revenue was $249.7 million versus $58.61 million expected, including licensing and milestone items tied to VEPPANU and Rigel. Management cited VEPPANU approval, upcoming Phase 1 data, and a cash runway into H2 2028.

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. arvn-20260624 0001655759 FALSE 0001655759 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. arvn-20260622 0001655759 FALSE 0001655759 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep

Bloomberg reports that Revolution Medicines’ daraxonrasib, a “molecular glue” drug, doubled median survival in aggressive pancreatic cancer from 6.7 to 13.2 months, with full phase 3 results expected at a Chicago conference. The success has spurred dealmaking and partnerships, including Monte Rosa’s potential $10B+ pacts with Novartis and Roche and J&J’s $3.05B Halda acquisition.

Pfizer and Arvinas have licensed global development and commercialization rights for VEPPANU, an FDA-approved oral PROTAC for breast cancer, to Rigel Pharmaceuticals. This deal allows Pfizer and Arvinas to receive royalties and milestone payments, shifting VEPPANU from a fully owned commercial effort to a royalty stream for Pfizer. The agreement enables Pfizer to reallocate resources to its broader oncology and PROTAC pipelines, introducing another potential source of future revenue for investors to track.

Arvinas reported a significant milestone with FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader, for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. Despite this approval, the company experienced a sharp revenue decline to $15.6 million from $188.8 million in the prior year and swung to a net loss of $57.6 million in Q1 2026. Arvinas maintains a strong cash position of $614.9 million, projected to fund operations into the second half of 2028, and continues to advance a broad PROTAC pipeline.

Guardant Health announced FDA approval for its Guardant360® CDx liquid biopsy as a companion diagnostic for VEPPANU (vepdegestrant), a treatment from Arvinas and Pfizer. This approval allows for the non-invasive identification of ER+/HER2- advanced breast cancer patients with ESR1 mutations who are eligible for VEPPANU. It marks Guardant's third ESR1 companion diagnostic approval and the 26th CDx indication for the Guardant360 CDx platform.